Overview: FLT3 Mutation TestIntroduction: The FLT3 Mutation Test detects FLT3 gene mutations to diagnose acute myeloid leukemia, causing fatigue or bruising. Following 2023 ASH guidelines, it uses PCR for high specificity, aiding in cancer screening. This test is critical for guiding diagnosis, treatment, and improving outcomes in molecular pathology for patients with suspected acute myeloid leukemia.
Other Names: FLT3 Mutation Assay, FMS-Like Tyrosine Kinase 3 Test.
FDA Status: Laboratory-developed test (LDT), meeting molecular pathology standards for diagnostic accuracy.
Historical Milestone: FLT3 mutation testing began in the 2000s with AML research. PCR-based assays emerged in the 2010s, improving accuracy for mutation detection.
Purpose: Diagnoses acute myeloid leukemia, guides targeted therapy, and monitors FLT3 mutations in patients with fatigue or bruising.
Test Parameters: 1. FLT3 Gene Mutation
Pretest Condition: No fasting required. Collect whole blood, bone marrow, or saliva at any time. Report symptoms like fatigue or bruising, and list medications.
Specimen: 2-5 mL whole blood (EDTA), 2-5 mL bone marrow (EDTA), or 1-2 mL saliva (sterile container). Transport in a biohazard bag within 24 hours.
Sample Stability at Room Temperature: 24 hours
Sample Stability at Refrigeration: 48 hours
Sample Stability at Frozen: Not frozen
Medical History: Document fatigue, bruising, or history of acute myeloid leukemia. Include current medications, especially targeted therapies.
Consent: Written consent required, detailing the tests purpose, diagnostic implications, and potential need for targeted therapy or genetic counseling.
Procedural Considerations: Uses PCR to detect FLT3 gene mutations (e.g., ITD, TKD). Results are available in 3-5 days, supporting clinical decisions.
Factors Affecting Result Accuracy: Low DNA yield or contamination can affect results. Rare mutations may require additional testing.
Clinical Significance: Positive FLT3 mutations confirm AML, prompting targeted therapy (e.g., midostaurin). Negative results may require further genetic testing.
Specialist Consultation: Consult a hematologist or oncologist for result interpretation.
Additional Supporting Tests: Bone marrow biopsy, other genetic tests (e.g., NPM1, CEBPA), or flow cytometry to confirm AML.
Test Limitations: False negatives may occur with rare mutations. Results require clinical correlation.
References: ASH Leukemia Guidelines, 2023; Blood, Döhner H, 2022.
